Novo Nordisk has committed $200 million to the World Diabetes Foundation from 2027 through 2036 to strengthen diabetes prevention and care, improve equitable access to services and support underserved communities in low- and middle-income countries. The long-term funding is intended to give the foundation greater certainty to plan, build partnerships and expand regional and global responses to the growing diabetes burden. World Diabetes Foundation managing director Leif Jensen said the pledge recognizes the organization’s 25-year effort to support people living with diabetes and related non-communicable diseases. The World Health Organization estimates that about 830 million people worldwide have diabetes; the earlier topic record cited 589 million adults aged 20–79 and estimated that about 80% live in low- and middle-income countries, reflecting different population definitions. Novo is seeking to recover ground from Eli Lilly in diabetes and obesity treatments, with Ozempic and Wegovy central to its strategy. Earlier this month, the company raised its 2026 outlook for the third time this year after quarterly sales of its Wegovy weight-loss pill exceeded forecasts.